Brazil’s semaglutide market expands rapidly with new registration ahead of pricing decision

Brazil’s diabetes drug market sees a swift increase in competition as EMS’s Yluméc gains regulatory approval, marking a significant shift following the patent expiry of Ozempic and Wegovy in the country.

Brazil’s fast-opening semaglutide market widened again on 31 August 2026, when Anvisa published the registration of Yluméc, a weekly EMS injection for adults with type 2 diabetes. The medicine uses semaglutide, the same active ingredient found in Novo Nordisk’s Ozempic and Wegovy, but it still cannot be sold until Brazil’s drug-pricing chamber, CMED, sets a maximum price. EMS has not said when pharmacies might begin stocking it. (agenciabrasil.ebc.com.br)

The approval matters less as a standalone launch than as another sign of how quickly competition has followed the end of Ozempic’s Brazilian patent on 20 March 2026. Folha reported that Yluméc gives EMS three semaglutide products in separate regulatory classes, strengthening its hand in a market that has become more contested since patent protection fell away. Agência Brasil said Ozivy, the company’s earlier branded semaglutide pen, was launched in June and now serves as Yluméc’s reference product. (agenciabrasil.ebc.com.br)

Rather than treating Yluméc as a generic, Anvisa placed it in the similar-medicine category under the “clone” route. That means the application is anchored to a previously cleared “matrix” medicine, in this case Ozivy, and can rely on part of the same technical and regulatory basis. When the regulator approved Ozivy on 26 May 2026, it said the product had first been filed in 2023 and described synthetic semaglutide analogues as a technical challenge for regulators around the world. At that stage, five other synthetic semaglutide medicines and one biological version were still under review, according to Anvisa. (gov.br)

CNN Brasil, citing Resolution-RE No 3.416 of 28 August 2026, said the Yluméc registration covers four commercial packs: a 1.5 mL cartridge with one pen and six needles; two 1.5 mL cartridges with two pens and 10 needles; a 3.0 mL cartridge with one pen and four needles; and two 3.0 mL cartridges with two pens and eight needles. CNN Brasil and the Associação Paulista de Medicina said the smaller presentation corresponds to four 0.25mg or 0.5mg applications, while the 3.0 mL version provides four 1mg or 2mg applications. The registration runs until August 2036 and the approved packs have a 24-month shelf life. (cnnbrasil.com.br)

EMS told Agência Brasil that Yluméc will be manufactured at its peptide plant in Hortolândia, in São Paulo state. The company signalled that approval is only one stage in the commercial process, saying that “definições estratégicas relacionadas ao planejamento comercial, preço e cronograma para o lançamento” would now come under discussion. That leaves open not only the launch date but also how EMS intends to position Yluméc alongside Ozivy and its generic semaglutide product. (agenciabrasil.ebc.com.br)

The timing is notable because Yluméc arrives after a run of August decisions that began to crowd Brazil’s post-patent semaglutide field. UOL and Folha reported that Anvisa had already approved EMS’s first generic semaglutide in mid-August, leaving the company with branded similar, generic and clone-style similar products in its portfolio. Both outlets also noted that generics in Brazil are sold under the substance name rather than a trade mark, while similar medicines such as Ozivy and Yluméc carry their own brands. (noticias.uol.com.br)

For patients, the authorised therapeutic use mirrors the indication Anvisa set out for Ozivy: adults with inadequately controlled type 2 diabetes, alongside diet and exercise, either on its own when metformin is unsuitable or in combination with other diabetes medicines. In its May notice on Ozivy, Anvisa also said the synthetic pen would be a weekly, prescription-only product requiring two copies of the prescription, and that it had to stay refrigerated at 2C to 8C throughout treatment, unlike Ozempic, which can remain at up to 30C for six weeks after first use. (gov.br)

The immediate result, then, is not another product on chemists’ shelves but another cleared file in a rapidly changing market. Until CMED signs off a ceiling price, Yluméc remains a registered medicine rather than a retail one. Even so, its approval on 31 August 2026 underlines how quickly Brazil has moved from a single semaglutide supplier to a more layered field of official alternatives after patent expiry, and how firmly EMS is trying to anchor itself in that new market. (agenciabrasil.ebc.com.br)